IP Library Granted Patent US 10,416,158
Granted Patent B2
US 10,416,158 · App. 14/643,693 · Granted Sep 17, 2019

Peptide MHCII tetramers to detect endogenous calnexin specific CD4 T cells

Inventors: Bruce Steven Klein (Madison, WI); Marcel Wuethrich (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
G01N33/56972G01N33/56961G01N2333/70539
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,416,158
App. No.
14/643,693
Granted
Sep 17, 2019
Kind
B2
Abstract

The present application discloses proteins or peptides and methods of using such proteins or peptides to evaluate the immune status of a patient. In one embodiment, proteins or peptides may be used to detect endogenous calnexin specific CD4 T cells. In one preferred embodiment, the proteins or peptides may comprise peptide-MHCII tetramers (pMHC tetramers).

Claims (16)

1. A composition to evaluate the immune status of a patient against a fungus, wherein the composition comprises peptide-MHCII tetramers comprising:

a calnexin peptide selected from the group consisting of SEQ ID NOs:1-5, 7 and 8 covalently linked by a flexible linker to a MHCII β chain; and

a MHCII α chain, wherein the β and α chains each further comprise a leucine zipper dimerization motif for association of said β and α chains.

2. The composition of claim 1 , additionally comprising at least one of a stabilizer, a buffer, or an adjuvant.

3. The composition of claim 1 , wherein the peptide-MHCII tetramers comprise at least one fluorescent label.

4. A kit for evaluating the immune status of a patient against a fungus comprising

(1) a container or formulation wherein the container or formulation comprises peptide-MHCII tetramers comprising:

a calnexin peptide selected from the group consisting of SEQ ID NOs:1-5, 7 and 8 covalently linked by a flexible linker to a MHCII β chain; and

a MHCII α chain, wherein the β and α chains each further comprise a leucine zipper dimerization motif for association of said β and α chains, and

(2) a detection marker for detecting helper T cells in a sample from the patient.

5. The kit of claim 4 , wherein the sample is a fresh blood sample.

6. The kit of claim 4 , wherein the peptide-MHCII tetramers are in the form of a powder.

7. The kit of claim 4 , wherein the peptide-MHCII tetramers are in a solution.

8. The kit of claim 4 , wherein the peptide-MHCII tetramers comprise at least one fluorescent label.

9. The kit of claim 4 , wherein the detection marker is a fluorescence label.

10. The kit of claim 4 , wherein the fungus is selected from a group consisting of Blastomyces dermatitidis, Histoplasma capsulatum, Aspergillus fumigatus, Fonsecea pedrosoi , and Geomyces destructans.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 17, 2018
From: WISCONSIN ALUMNI RESEARCH FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046179/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2015
From: WUETHRICH, MARCEL; KLEIN, BRUCE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 036028/0261 →
Continuity (2)
Provisional Application 61951099 · Mar 11, 2014
Related Publication 20150301044A1 · Oct 22, 2015